BPTSY
Price
$2.08
Change
+$0.14 (+7.22%)
Updated
May 8 closing price
Capitalization
3.39M
PRVCF
Price
$0.02
Change
-$0.00 (-0.00%)
Updated
May 9 closing price
Capitalization
13.61M
Ad is loading...

BPTSY vs PRVCF

Header iconBPTSY vs PRVCF Comparison
Open Charts BPTSY vs PRVCFBanner chart's image
Biophytis SA
Price$2.08
Change+$0.14 (+7.22%)
Volume$500
Capitalization3.39M
PreveCeutical Medical
Price$0.02
Change-$0.00 (-0.00%)
Volume$55.65K
Capitalization13.61M
BPTSY vs PRVCF Comparison Chart
Loading...
View a ticker or compare two or three
VS
BPTSY vs. PRVCF commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BPTSY is a Hold and PRVCF is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (BPTSY: $2.08 vs. PRVCF: $0.02)
Brand notoriety: BPTSY and PRVCF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BPTSY: 255% vs. PRVCF: 78%
Market capitalization -- BPTSY: $3.39M vs. PRVCF: $13.61M
BPTSY [@Biotechnology] is valued at $3.39M. PRVCF’s [@Biotechnology] market capitalization is $13.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BPTSY’s FA Score shows that 0 FA rating(s) are green whilePRVCF’s FA Score has 0 green FA rating(s).

  • BPTSY’s FA Score: 0 green, 5 red.
  • PRVCF’s FA Score: 0 green, 5 red.
According to our system of comparison, both BPTSY and PRVCF are a bad buy in the long-term.

Price Growth

BPTSY (@Biotechnology) experienced а +7.22% price change this week, while PRVCF (@Biotechnology) price change was -3.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
PRVCF($13.6M) has a higher market cap than BPTSY($3.39M). PRVCF YTD gains are higher at: 26.087 vs. BPTSY (-32.686). PRVCF has higher annual earnings (EBITDA): -1.02M vs. BPTSY (-15.13M). BPTSY (0) and PRVCF (0) have equivalent revenues.
BPTSYPRVCFBPTSY / PRVCF
Capitalization3.39M13.6M25%
EBITDA-15.13M-1.02M1,481%
Gain YTD-32.68626.087-125%
P/E RatioN/AN/A-
Revenue00-
Total CashN/A236-
Total DebtN/A4.3M-
FUNDAMENTALS RATINGS
PRVCF: Fundamental Ratings
PRVCF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
85
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRVS4.431.08
+32.24%
Corvus Pharmaceuticals
FTEK0.970.02
+1.89%
Fuel Tech
OZK44.61-0.22
-0.49%
Bank OZK
JD33.86-0.26
-0.76%
JD.com
PDFS18.41-1.19
-6.07%
PDF Solutions

BPTSY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BPTSY has been closely correlated with CDTX. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if BPTSY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BPTSY
1D Price
Change %
BPTSY100%
N/A
CDTX - BPTSY
92%
Closely correlated
-2.72%
NGNE - BPTSY
38%
Loosely correlated
-1.80%
RNAZ - BPTSY
36%
Loosely correlated
-2.40%
VRCA - BPTSY
27%
Poorly correlated
+5.97%
BRNS - BPTSY
26%
Poorly correlated
-3.67%
More

PRVCF and

Correlation & Price change

A.I.dvisor tells us that PRVCF and BPTSY have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PRVCF and BPTSY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRVCF
1D Price
Change %
PRVCF100%
+3.57%
BPTSY - PRVCF
21%
Poorly correlated
N/A
GLMD - PRVCF
20%
Poorly correlated
-0.80%
ARTL - PRVCF
20%
Poorly correlated
+2.00%
SBHMY - PRVCF
9%
Poorly correlated
N/A
PXXLF - PRVCF
7%
Poorly correlated
N/A
More